Actively Recruiting
Study of Bone Health in Adolescents and Young Adults Aged 12 to 21 With Obesity Using GLP-1 Receptor Agonist Therapy Compared to Lifestyle Management
Led by University of Virginia · Updated on 2026-04-17
120
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are investigating bone health in adolescents and young adults aged 12 to 21 years with obesity who are starting treatment with glucagon-like peptide-1 receptor agonists GLP-1RAs compared to those with similar weight who follow lifestyle management alone. The study aims to understand whether GLP-1 RA therapy affects bone density, geometry, strength, and bone turnover markers over a 24-month period, as bone health is a concern during weight loss treatments in this age group. This phase 2, non-randomized observational trial is sponsored by the University of Virginia and addresses gaps in knowledge about bone effects of GLP-1RAs in youth compared to adults and surgery outcomes.
CONDITIONS
Brief Title
Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist Therapy
Research Team
M
Madhusmita Misra, MD, MPH
C
Christine Burt Solorzano, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
